ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AMBR Ambrian

1.50
0.00 (0.00%)
22 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ambrian LSE:AMBR London Ordinary Share GB0003763140 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.50 1.25 1.75 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Ambrian Hires Leading Life Sciences Equities Team

05/01/2010 7:00am

RNS Non-Regulatory



 

TIDMAMBR 
 
 
Ambrian Capital PLC 
05 January 2010 
 
Embargoed: 0700hrs, 5 January 2010 
 
 
Ambrian Capital plc 
 
 
Ambrian Hires Leading Life Sciences Equities Team 
 
 
LONDON, 5 January 2010 - Ambrian Partners Limited ("Ambrian"), a wholly-owned 
subsidiary of Ambrian Capital plc, has hired a leading life sciences equities 
team to be led by Julian Burn-Callander, a former Head of Equity Sales and 
founding partner of Code (now Nomura Code) Securities. 
 
 
Prior to Nomura Code Securities Julian Burn-Callander, who has been in the 
equity markets for over thirty years, previously led Healthcare Specialist Sales 
at Panmure Gordon and was formerly Head of Equity Sales at SocGen. He will be 
joined by three highly experienced life sciences analysts, also founding 
partners of Code Securities: Paul Diggle, Mike Ward and Dr Chris Redhead. 
 
 
Paul Diggle, who has held a number of senior life sciences research positions 
including Head of Global Healthcare at S.G. Warburg, will initiate coverage of 
European large-cap pharmaceutical companies. Paul will work alongside Mike Ward, 
a specialist salesman and analyst who has held positions at both NatWest Markets 
and Deutsche Bank. Earlier in his career Mike spent a number of years at Glaxo 
Holdings and Sandoz (now Novartis). 
 
 
Dr Chris Redhead has more than ten years experience providing investment 
research of small and mid-cap biotechnology, diagnostics and, more latterly, 
biologically-based cleantech companies. He has played a pivotal role in a range 
of significant fund-raisings and M&A transactions in the European life sciences 
sector and, together with Julian Burn-Callander, will form a strong team focused 
on small and mid-cap corporate client opportunities. 
 
 
Richard Chase, Managing Director of Ambrian Partners, commented, 
 
 
"Ambrian Partners is seeking to build on its strong market positions in metals & 
mining, oil & gas and cleantech by hiring leading teams and individuals in 
certain key growth sectors. Julian and the team are very highly respected and 
are sure to make an important contribution as we seek to broaden the range of 
our specialist sectors. We are delighted to have recruited one of the top 
healthcare equities teams in the City." 
 
 
- Ends - 
 
 
For further press information please contact: 
 
 
Richard Chase, Managing Director 
Ambrian Partners Limited 
+44 (0)207 634 4700 
 
 
Ben Simons or Charlotte Kirkham 
M: Communications 
+44 (0)207 920 2340 / 2331 
 
 
About Ambrian Capital plc 
Ambrian Capital (AIM: AMBR) is the holding company of Ambrian Partners Limited, 
Ambrian Commodities Limited and Ambrian Metals Limited. 
Ambrian Partners Limited is a focused investment bank known in the market today 
for its leading positions in the metals & mining, oil & gas and cleantech 
sectors. It provides corporate finance advice, equity research, sales and 
trading and market making services. Ambrian Partners has been ranked first in 
the AIM Basic Materials Sector in the Hemscott Advisers Rankings and was voted 
No. 1 for small and mid-cap mining in the Extel Survey of fund managers in 2009. 
Ambrian Partners is a member of the London Stock Exchange and is authorised and 
regulated by the Financial Services Authority. 
For further information on Ambrian Capital, please visit: www.ambrian.com 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRAUGURAGUPUGQC 
 

1 Year Ambrian Capital Chart

1 Year Ambrian Capital Chart

1 Month Ambrian Capital Chart

1 Month Ambrian Capital Chart